Introduction
Preterm birth -delivery before 37 completed weeks of gestation -is the leading cause of neonatal morbidity and mortality worldwide [1, 2] . Two-thirds of all preterm births are preceded by spontaneous preterm labour [3, 4] , a syndrome of multiple aetiologies [5] . Pathological inflammation is implicated in the mechanisms responsible for spontaneous preterm labour [6] [7] [8] and is mainly attributed to the activation of the innate limb of immunity [8] [9] [10] [11] [12] [13] [14] [15] [16] . Indeed, innate lymphocytes, such as invariant natural killer T (iNKT) cells, participate in the inflammatory mechanisms that lead to preterm labour and birth [17] [18] [19] .
iNKT cells express a CD1d-restricted T-cell receptor (TCR) that involves the selective use of Va14 in mice [20] and Va24 in humans [21] , both of which recognize lipid antigens [22] . Activation of iNKT cells can initiate the nuclear factor kappa B (NF-jB) signalling pathway, which leads to a massive immune response mediated by T helper type 1 (Th1) and Th2 cytokines [23] [24] [25] [26] . In vivo and direct activation of iNKT cells is achieved by the administration of the high-affinity ligand a-galactosylceramide (a-GalCer) V C 2017 British Society for Immunology, Clinical and Experimental Immunology, 189: 211-225 [27, 28] . Recently, we demonstrated that the in vivo and direct activation of iNKT cells via a-GalCer initiates systemic and local (i.e. decidua and myometrium) immune responses leading to preterm labour/birth [19] . Such responses are largely mediated by cellular components of the innate immune system, such as neutrophils, macrophages and dendritic cells [19] . However, iNKT cells bridge the innate and adaptive limbs of immunity [29] ; therefore, we propose that such cells have an effect on T cells, the main cellular component of the adaptive immune system. T cells have been implicated in the mechanisms that lead to term [30] [31] [32] [33] [34] and preterm [31, 32, [35] [36] [37] [38] [39] [40] [41] [42] labour. Indeed, in vivo activation of T cells through the stimulation of the CD3 complex induces preterm labour/birth [43] . In the current study, we investigated whether iNKT-cell activation via a-GalCer has an effect on systemic and local T-cell subsets prior to preterm labour/birth.
In vivo iNKT-cell activation via a-GalCer down-regulates the expression of peroxisome proliferator-activated receptor gamma (PPARg) target genes such as Fabp4 and Fatp4 [19] . However, treatment with rosiglitazone, a selective PPARg agonist [44] , restores the expression of such genes and reduces the rate of iNKT-cell activation-induced preterm labour/birth [19] . Rosiglitazone activates the PPARg pathway, which interferes with the NF-jB, signal transducer and activator of transcription (STAT), and activator protein (AP)-1 signalling pathways, inhibiting the gene transcription of inflammatory mediators [45] [46] [47] . Herein, we investigated whether treatment with rosiglitazone restores the effect of iNKT-cell activation on local and systemic T-cell subsets.
Materials and methods

Animals
C57BL/6J (B6) mice were bred in the animal care facility at the C.S. Mott Center for Human Growth and Development (Wayne State University, Detroit, MI, USA) and housed under a circadian cycle (12-h light/12-h dark). Females 8-12 weeks old were mated with males of proven fertility. Females were examined daily between 8:00 a.m. and 9:00 a.m., and mating was verified by the presence of a vaginal plug, indicating 0Á5 days post coitum (dpc). After observation of the vaginal plug, females were separated from males and placed into new cages. A weight gain of > 2 g by 12Á5 dpc confirmed pregnancy. Procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Wayne State University (Protocol number A-09-08-12).
iNKT-cell activation-induced preterm labour/birth model Pregnant B6 mice were intravenously (i.v.) injected with 2 mg of a-GalCer (KRN7000; Funakoshi, Tokyo, Japan; n 5 8) that was dissolved in 50 mL of 4% dimethyl sulphoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA) or with 50 mL of 4% DMSO alone as a control (n 5 6) at 16Á5 dpc.
Rosiglitazone treatment
Pregnant B6 mice were i.v. injected with 2 mg of a-GalCer at 16Á5 dpc (n 5 8). After 2 h, mice were subcutaneously (s.c.) injected with rosiglitazone (10 mg/kg; Selleck Chemicals, Houston, TX, USA) diluted in 1:10 DMSO. Control mice were treated with rosiglitazone alone at 16Á5 dpc (n 5 8).
Tissue collection and leucocyte isolation
Pregnant mice were euthanized 6 h post-a-GalCer or post-DMSO injection, or 4 h post-rosiglitazone treatment (n 5 6-8 mice/group). Blood was recovered by cardiac puncture, and the myometrial and decidual tissues were collected and immediately processed for leucocyte isolation. The spleen and uterine-draining lymph nodes (ULNs) were also collected and leucocyte suspensions were prepared.
Leucocyte suspensions from the myometrial and decidual tissues were prepared as follows: tissues were cut into small pieces using fine scissors and enzymatically digested with StemPro Cell Dissociation Reagent (Accutase; Life Technologies, Grand Island, NY, USA) for 35 min at 378C. Cells from the spleen and ULNs were obtained by gentle dissociation using two glass slides. Leucocyte suspensions from the myometrium, decidua, spleen and ULNs were then filtered through a 100-mm cell strainer (Fisher Scientific, Hanover Park, IL, USA) and washed with fluorescence activated cell sorter (FACS) buffer [0Á1% bovine serum albumin (Sigma-Aldrich), 0Á05% sodium azide (Fisher Scientific, Fair Lawn, NJ, USA) and 13 phosphate-buffered saline (PBS; Fisher Scientific)].
Immunophenotyping
Aliquots of 100-150 lL of blood were used for immunophenotyping. Leucocyte suspensions from the myometrium and decidua were stained with the LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Life Technologies) prior to incubation with extracellular monoclonal antibodies (mAbs). All leucocyte suspensions and blood samples were centrifuged, and cell pellets were incubated for 10 min with CD16/CD32 mAbs (FcgIII/II Receptor, clone 2.4G2; BD Biosciences, San Jose, CA, USA) and subsequently incubated with specific fluorochrome-conjugated anti-mouse mAbs: CD1d-tetramer loaded with a-GalCer-phycoerythrin (PE) (hereafter referred to as CD1d-tetramer, NIH), CD49b/DX5-allophycocyanin (APC) (clone DX5), CD44-APC-cyanin 7 (Cy7) (clone IM7), CD69-PE-CF594 (clone H1.2F3), CD3E-APC-Cy7 (clone 145-2C11), CD4-APC (clone RM4-5), CD8a-PE-CF594 (clone 
Statistical analysis
Flow cytometry data were analysed using the IBM SPSS software version 19 (IBM Corporation, Armonk, NY, USA). The statistical significance of group comparisons was assessed using Mann-Whitney U-tests. A P-value of 0Á05 was considered statistically significant.
Results
Administration of a-GalCer induces iNKT-cell activation in the decidua
First, we confirmed that a-GalCer induced iNKT-cell activation in the decidual tissues [19] . Activated CD1d-restricted iNKT cells were identified in the decidua by the expression of the CD1d-tetramer and DX5 antigen as well as the co-expression of CD69 and CD44 antigens (Fig. 1a) . Administration of a-GalCer induced the proliferation of activated CD1d-restricted iNKT cells in the decidua (Fig. 1b) .
iNKT-cell activation causes a systemic and local reduction of T cells through the CD3E molecule prior to preterm labour/birth
We investigated whether iNKT-cell activation via a-GalCer alters systemic and local T cells prior to preterm labour/ birth. The gating strategy used to determine total T cells (CD3 Fig. 2d ) compared to the DMSO controls. Although not significant, there was a modest reduction in the number of decidual T cells between the mice injected with a-GalCer and the DMSO controls (Fig. 2e) .
As we observed a reduction in the total number of T cells, we evaluated the mean fluorescence intensity (MFI) of the CD3E molecule in leucocytes from the periphery, lymphatic tissues and maternal-fetal interface. Administration of a-GalCer down-regulated the expression of the CD3E molecule in the leucocytes from the periphery (Fig.  3a) , spleen ( Fig. 3b) , ULNs ( Fig. 3c ) and decidua ( Fig. 3e) . Alterations in T-cell subsets prior to iNKT-cell activation-induced preterm birth Administration of a-GalCer did not have any effect on the CD3E molecule in the myometrial leucocytes (Fig. 3d) . In order to investigate whether iNKT-cell activation induced cell death in the decidua, we evaluated the viability of decidual lymphocytes from mice injected with a-GalCer or DMSO. There were no differences in the number of viable cells between these two groups (Supporting information, Fig. S2 ). iNKT-cell activation causes a systemic and local reduction of conventional and regulatory CD4
1 T cells prior to preterm labour/birth
Conventional and regulatory CD4
1 T cells have been implicated in the processes of term and preterm labour [19, 31, 33, 34, [36] [37] [38] 41] . We evaluated whether conventional CD4 1 T cells would be reduced upon the administration of a-GalCer. The gating strategy used to determine conventional CD4 1 T cells in the tissues and blood is shown in T cells between the mice injected with a-GalCer and the DMSO controls in the decidua (Fig. 4f) . Next, we evaluated whether there was a systemic and local reduction of CD4 1 T regs prior to iNKT-cell activation-induced preterm labour/birth. The gating strategy used to determine CD4 1 T regs in the spleen, ULNs and decidua is shown in Fig. 5a -c. Mice injected with a-GalCer had a lower number of CD4 1 T regs in the spleen (Fig. 5d) and ULNs (Fig. 5e ) than the DMSO controls. The number of decidual CD4 1 T regs also decreased in 62Á5% (five out of eight) of the mice injected with a-GalCer; however, this reduction did not reach statistical significance (Fig. 5f ). No differences were observed in the number of CD4 1 T regs in the peripheral blood and myometrium upon administration of a-GalCer (data not shown).
iNKT-cell activation alters the number of Th17 cells in the uterine-draining lymph nodes and decidua prior to preterm labour/birth
An imbalance between the effector Th17 cells and CD4
1
T regs may be implicated in the pathogenesis of preterm birth [48] . Therefore, we evaluated whether there were systemic and local reductions of Th17 cells prior to iNKT-cell activation-induced preterm labour/birth. The gating strategy used to determine Th17 cells in the ULNs, spleen and decidua is shown in Fig. 6a -c. Mice injected with a-GalCer had a reduced number of Th17 cells in the ULNs (Fig. 6d) and spleen ( Fig. 6e ; not significant) compared to the DMSO controls. However, mice injected with a-GalCer had a greater number of decidual Th17 cells than the DMSO controls (Fig. 6f) . No differences were observed in the number of Th17 cells in the peripheral blood and myometrium upon administration of a-GalCer (data not shown).
iNKT-cell activation causes a systemic and local reduction of CD8 1 T cells prior to preterm labour/ birth CD8 1 cytotoxic T cells have been implicated in the mechanisms that lead to spontaneous preterm labour [40] . Next, Alterations in T-cell subsets prior to iNKT-cell activation-induced preterm birth we evaluated whether CD8 1 T cells were reduced upon administration of a-GalCer. The gating strategy used to determine CD8 1 T cells in the tissues and blood is shown in Fig. 7a . Mice injected with a-GalCer had a lower number of CD8 1 T cells in the peripheral blood (Fig. 7b) , spleen ( Fig. 7c) , ULNs (Fig. 7d) , myometrium ( Fig. 7e) and decidua (Fig. 7f) than the DMSO controls.
iNKT-cell activation causes a reduction of CD8 1 regulatory T cells in the spleen and uterine-draining lymph nodes prior to preterm labour/birth
Previous studies have demonstrated that CD8 1 T regs are implicated in the timing of term parturition [34] and endotoxin-induced preterm labour/birth [41] . Therefore, we evaluated whether there was a systemic and local reduction of CD8 1 T regs prior to iNKT-cell activation-induced preterm labour/birth. The gating strategy used to determine CD8 1 T regs in the spleen and ULNs is shown in Fig.   8a ,b. Mice injected with a-GalCer had a lower number of CD8 1 T regs in the spleen (Fig. 8c) and ULNs (Fig. 8d) (Fig. 9a,d ) and ULNs (Fig. 9b,e) . In the decidua, a-GalCer did not reduce the number of CD4 1 Foxp3 -responder T cells (Fig. 9c) ; however, it partially decreased the number of CD8 1 Foxp3 -responder T cells (Fig. 9f ).
iNKT-cell activation causes a reduction in the number of double-negative T cells prior to preterm labour/birth
Lastly, we evaluated whether there were alterations in the number of double-negative T cells (CD3 N. Gomez-Lopez et al. Alterations in T-cell subsets prior to iNKT-cell activation-induced preterm birth 
Treatment with rosiglitazone partially restores the number of T cells in the spleen but not in the decidua
Previous studies demonstrated that treatment with rosiglitazone prevents endotoxin-induced [13] and iNKT-cell activation-induced [19] preterm labour/birth. Herein, we investigated whether treatment with rosiglitazone restores the effect of iNKT-cell activation on systemic and local T cells prior to preterm labour/birth. Treating a-GalCerinjected mice with rosiglitazone partially increased the number of total T cells (Fig. 10a) , CD4 1 T cells (Fig. 10b) and CD8 1 T cells (Fig. 10c) in the spleen; however, such increments did not reach statistical significance. In contrast, treatment with rosiglitazone did not restore the T-cell numbers in the decidual tissues (Fig. 10d-f) . Further, we investigated whether treatment with rosiglitazone restored the number of CD4 1 T regs in the decidua. Treating aGalCer-injected mice with rosiglitazone did not restore the number of CD4 1 T regs in the decidua (Supporting information, Fig. S4 ) and spleen (data not shown).
Discussion
Principal findings of the study
Administration of a-GalCer induced an expansion of CD1d-restricted iNKT cells in the decidua. Prior to iNKTcell activation-induced preterm labour/birth, there was (1) a reduction in the number of total T cells, including CD4 Collectively, these data show that iNKT-cell activation via a-GalCer induces the down-regulation of the CD3E molecule, which translates to an alteration in the systemic and local T-cell numbers prior to preterm labour/birth; however, treatment with rosiglitazone partially reversed such effects.
Recently, we demonstrated that in vivo T-cell activation by administration of a monoclonal aCD3E antibody (clone 145-2C11) induces preterm labour/birth [43] . This monoclonal aCD3E antibody activates T cells in the absence of antigens by directly recognizing the CD3E molecule and evading the T-cell receptor antigen-specific interaction [49, 50] . In vitro and in vivo studies have demonstrated that the interaction between aCD3E and the CD3 molecule initiates endocytosis and a temporary loss of the CD3/TCR complex [51] [52] [53] [54] . However, such an interaction initiates signalling pathways simultaneously that result in T-cell activation [55] [56] [57] . Therefore, in vivo and in vitro T-cell activation is associated with the temporary loss of the CD3E molecule [57] . In the current study, we found that iNKT-cell activation via a-GalCer caused the downregulation of the CD3E molecule, which translated to a reduction in the total number of systemic and local T cells. These findings provide evidence that a-GalCer induces in vivo T-cell activation prior to causing preterm labour/ birth. In line with this concept, we have previously demonstrated that prior to iNKT-cell activation-induced preterm labour/birth, there is an up-regulation of the CD25 and PD1 molecules (activation markers) in the myometrial CD4 1 T cells [19] . In addition, administration of a-GalCer to non-pregnant mice induces the up-regulation of CD69 (an early activation marker) in splenocytes [58] . Taken together, these results suggest that a-GalCer causes the systemic and local down-regulation of the CD3E molecule (i.e. T-cell activation) prior to preterm labour/birth. In this study, we found that lymphatic and decidual CD4 1 T regs were reduced prior to iNKT-cell activationinduced preterm labour/birth. CD4 1 T regs are T lymphocytes that express the activation marker CD25 and the transcription factor Foxp3 [59, 60] . Their suppressive function is largely due to the expression of Foxp3 [59, 60] . During pregnancy, there is an expansion of antigen-specific Alterations in T-cell subsets prior to iNKT-cell activation-induced preterm birth 
CD4
1 T regs in the spleen and at the maternal-fetal interface, which promotes maternal-fetal tolerance and pregnancy maintenance [61] [62] [63] [64] . Indeed, a reduction in the frequency and/or suppressive function of circulating CD4
1
T regs is associated with spontaneous preterm labour [31, 32, 37, 38, 65, 66] . In addition, a decline in the number of CD4 1 T regs at the maternal-fetal interface is observed prior to endotoxin-induced preterm labur/birth [41] . These data support the hypothesis that a breakdown of maternal-fetal tolerance is a mechanism of disease contributing to spontaneous preterm labour [5, 39] . Together, these findings allow us to hypothesize that iNKT-cell activation via a-GalCer causes a breakdown of maternal-fetal tolerance by reducing lymphatic and decidual CD4 1 T regs prior to preterm labour/birth. This hypothesis is supported by the fact that activated iNKT cells regulate CD4 1 T regs negatively [67] .
Although decidual CD4 1 Foxp3 -responder T cells were not altered prior to iNKT-cell activation-induced preterm labour/birth, the number of decidual Th17 cells was increased. The Th17 cell subset is characterized by the expression of IL-17A, IL-17F and IL-22 [68] . The functions of these T cells are wide-ranging, as these cells can promote or regulate tissue inflammation [68, 69] . Th17 cells are present in the decidual tissues from normal pregnancies [70] , and placental hormones (e.g. human chorionic gonadotrophin [71] ) may be participating in their proliferation/ differentiation. Decidual Th17 cells are also abundant in the chorioamniotic membranes from women who underwent spontaneous preterm labour with acute histologic chorioamnionitis [72] . In fact, an imbalance between effector Th17 cells and CD4 1 T regs has been implicated in the pathogenesis of preterm birth [48] . The data presented herein suggest that iNKT-cell activation via a-GalCer induces T-cell activation and therefore promotes the differentiation of effector Th17 cells at the maternal-fetal interface. This observation is concordant with the fact that iNKT-cell activation induces the activation of T cells [19] and iNKT null mice (Ja281
) have a lower number of Th17 cells [73] . Collectively, these findings indicate that, prior to iNKT-cell activation-induced preterm labour/birth, there is an imbalance between CD4
1 T regs and Th17 cells at the maternal-fetal interface.
In addition to altering the number of Th cell subsets, iNKT-cell activation via a-GalCer reduced the number of lymphatic CD8 ) received recombinant IL-6 in order to restore the timing of parturition [34] . Altogether, these data suggest that CD8 1 T regs can regulate the timing of parturition and that a reduction in the number of these cells may be associated with preterm labour/ birth. Lastly, we showed that treating a-GalCer-injected mice with rosiglitazone, which prevents iNKT-cell activationinduced preterm labour/birth [19] , partially restores the T-cell numbers in the spleen. It is well established that PPARg agonists, such as rosiglitazone, inhibit the activation and proliferation of T cells [76, 77] . In our model, we demonstrated that a-GalCer down-regulated PPARg gene targets; however, treatment with rosiglitazone restored such effects by activating the PPARg pathway and preventing preterm labour/birth [19] . Therefore, restoration of the T-cell numbers in the spleen may be explained by the fact that rosiglitazone inhibits iNKT-cell proliferation [19] , the initial trigger of T-cell activation (i.e. down-regulation of the CD3/TCR complex). However, treating a-GalCerinjected mice with rosiglitazone did not restore the number of T cells, including CD4
1 T regs , at the maternal-fetal interface (i.e. decidua). This finding may explain why treatment In vivo iNKT-cell activation via a-galactosylceramide (a-GalCer) induces T-cell activation (down-regulation of the CD3E molecule), which translates into alterations in T-cell subsets at the maternal-fetal interface prior to preterm labour/birth. In addition, in vivo iNKT-cell activation induces the activation of the innate immune system and decidual cells (maternal-fetal interface) prior to preterm labour/birth [19] . Peroxisome proliferator-activated receptor gamma (PPARg) activation via treatment with rosiglitazone could partially restore such effects and prevent preterm labour/birth.
Alterations in T-cell subsets prior to iNKT-cell activation-induced preterm birth . In summary, this study showed that iNKT-cell activation via a-GalCer induced T-cell activation (i.e. downregulation of the CD3E molecule), which translated to a systemic and local alteration in T-cell subsets prior to preterm labour/birth; however, treatment with rosiglitazone partially restored such effects (Fig. 11) . Previously, we have demonstrated that in vivo iNKT-cell activation induces the activation of the innate immune system (macrophages, dendritic cells and neutrophils) and decidual cells (maternal-fetal interface) prior to preterm labour and birth, which is also attenuated upon treatment with rosiglitazone [19] (Fig. 11) . Together, these findings provide evidence that both innate and adaptive immune cells are implicated in the pathogenesis of preterm labour and that PPARg activation can represent a strategy for the prevention of this syndrome (Fig. 11) . However, a combination of therapeutic approaches may be required to prevent preterm labour/ birth entirely and to improve adverse neonatal outcomes. 
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Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Gating strategy used to determine viable T cells in the decidua and uterine-draining lymph nodes (ULNs). Lymphocytes were gated using the forward (FSC) and side-scatter (SSC) parameters. Next, viable cells (negative cells for the live/dead dye) were gated within the lymphocyte gate. Lastly, T cells were determined by the expression of CD3E. The red histogram represents the autofluorescence control and the blue histogram represents the fluorescence signal from the viability dye or the anti-CD3E antibody. Fig. S2 . Administration of a-galactosylceramide (aGalCer) did not cause cell death in decidual cells. Number of viable cells in the decidua from mice injected with dimethyl sulphoxide (DMSO, control) or a-GalCer (n 5 6-8 each). (e) and decidua (f) from mice injected with dimethyl sulphoxide (DMSO, control) or a-GalCer (n 5 6-8 each). Fig. S4 . Treating a-galactosylceramide (a-GalCer)-injected mice with rosiglitazone did not restore the number of CD4 1 regulatory T cells (T regs ) in the decidua. Number of CD4 1 T regs in the decidua from mice injected with dimethyl sulphoxide (DMSO, control), a-GalCer, rosiglitazone (Rosi) or a-GalCer plus rosiglitazone (n 5 6-8 each).
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